Immunoglobulin News and Research

RSS

Scientists discover how lymphotoxin controls production of immunoglobulins in gut

Lymphotoxin is a cytokine, or intercellular messenger, and plays an important role in the immunological balance of the gastrointestinal tract. It regulates the immune system of the digestive tract, which is made up of immune cells, immunoglobulins (antibodies) as well as intestinal bacteria.

10 Dec 2013

Autumn-born children prone to asthma

Month of birth closely correlates with the prevalence of bronchial asthma, a major study of Taiwanese children has found.

5 Dec 2013

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

5 Dec 2013

New evidence-based guidelines for diagnosis and assessment of atopic dermatitis

The American Academy of Dermatology (Academy) has released new evidence-based guidelines for the diagnosis and assessment of atopic dermatitis based on an extensive review of the scientific literature on this chronic skin condition characterized by itchy red patches of skin.

5 Dec 2013

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.

5 Dec 2013

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.

3 Dec 2013

Researchers discover powerful mechanism that keeps white blood cells from going rogue

The immune system is a double-edged sword. While its primary role is to fight infections, it can also become overactive, leading to problems like allergies and autoimmune diseases.

13 Nov 2013

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

IVIG is a hugely successful biological with FDA approval for treating idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome, Graves ophthalmopathy and numerous polyneuropathies.

11 Nov 2013

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Specific antibody patterns predict schizophrenia risk

The presence of antibodies to multiple foods and infectious agents is a risk marker for new-onset schizophrenia, a case-control study suggests.

23 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

18 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

17 Oct 2013

New mathematical model predicts biological process that creates antibody diversity

Scientists at USC have created a mathematical model that explains and predicts the biological process that creates antibody diversity - the phenomenon that keeps us healthy by generating robust immune systems through hypermutation.

9 Oct 2013

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

Professor Richard Pleass has won the Prix de l’Innovation 2013, also known as the Universal Biotech Innovation Prize 2013.

8 Oct 2013

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

Haemtech Biopharma Services (HBS) is pleased to announce the successful validation of a thrombin generation assay (TGA) for an IVIG drug. The assay was validated in 2012 to support the use of TGA as a release assay for Biotest Pharmaceuticals Corporation's U.S. Food and Drug Administration Biologics License Application for BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] product. The validated TGA assay was designed and performed on the Calibrated Automated Thrombogram® platform (CAT) from Diagnostica Stago, Inc. (Parsippany, NJ).

1 Oct 2013

Pfizer Licenses Gliknik's Pooled IVIG In $25M+ Deal

...

30 Sep 2013

FDA expands Hizentra administration options for people with primary immunodeficiency

CSL Behring announced today that the U.S. Food and Drug Administration has expanded the administration options for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, to include dosing once every two weeks (biweekly) for people diagnosed with primary immunodeficiency.

28 Sep 2013

Japanese MHLW approves Hizentra for treatment of primary and secondary immunodeficiencies

CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and serious diseases of the immune system.

27 Sep 2013

T. gondii antibodies implicated in mania

Infection with Toxoplasma gondii may confer an increased risk for mania, say researchers.

26 Sep 2013

Inflammation tracks mania course

Markers of inflammation are elevated in patients who are hospitalized for acute mania, a study shows.

24 Sep 2013

Immunoglobulin News and Research

Scientists discover how lymphotoxin controls production of immunoglobulins in gut

Autumn-born children prone to asthma

EMA expands administration options for Hizentra

New evidence-based guidelines for diagnosis and assessment of atopic dermatitis

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Researchers discover powerful mechanism that keeps white blood cells from going rogue

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Specific antibody patterns predict schizophrenia risk

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

New mathematical model predicts biological process that creates antibody diversity

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

Pfizer Licenses Gliknik's Pooled IVIG In $25M+ Deal

FDA expands Hizentra administration options for people with primary immunodeficiency

Japanese MHLW approves Hizentra for treatment of primary and secondary immunodeficiencies

T. gondii antibodies implicated in mania

Inflammation tracks mania course

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News